Aging tilts the balance in favor of adipocyte differentiation at the expense of osteoblast differentiation, resulting in reduced bone formation and osteopenic disorders, including osteoporosis, in humans and animals. Understanding the mechanisms involved in causing this apparent shift in differentiation, and identifying factors that stimulate osteoblast formation while inhibiting adipogenesis is of great therapeutic interest. In this study we report that specific, naturally-occurring oxysterols, previously shown to direct pluripotent mesenchymal cells toward an osteoblast lineage, exert their osteoinductive effects through activation of Hedgehog signaling pathway. This was demonstrated by 1) oxysterol-induced expression of the Hh target genes Gli-1 and Patched, 2) oxysterolinduced activation of a luciferase reporter driven by a multimerized Gli-responsive element, 3) inhibition of oxysterol effects by the hedgehog pathway inhibitor, cyclopamine, and 4) unresponsiveness of Smoothened-/-mouse embryonic fibroblasts to oxysterols. Using Patched-/-cells that possess high baseline Gli activity, we found that oxysterols did not dramatically shift the IC50 concentration of cyclopamine needed to inhibit Gli activity in these cells.
Pluripotent mesenchymal cells form a population of precursors to a variety of cell types including osteoblasts and adipocytes.
Aging tilts the balance in favor of adipocyte differentiation at the expense of osteoblast differentiation, resulting in reduced bone formation and osteopenic disorders, including osteoporosis, in humans and animals. Understanding the mechanisms involved in causing this apparent shift in differentiation, and identifying factors that stimulate osteoblast formation while inhibiting adipogenesis is of great therapeutic interest. In this study we report that specific, naturally-occurring oxysterols, previously shown to direct pluripotent mesenchymal cells toward an osteoblast lineage, exert their osteoinductive effects through activation of Hedgehog signaling pathway. This was demonstrated by 1) oxysterol-induced expression of the Hh target genes Gli-1 and Patched, 2) oxysterolinduced activation of a luciferase reporter driven by a multimerized Gli-responsive element, 3) inhibition of oxysterol effects by the hedgehog pathway inhibitor, cyclopamine, and 4) unresponsiveness of Smoothened-/-mouse embryonic fibroblasts to oxysterols. Using Patched-/-cells that possess high baseline Gli activity, we found that oxysterols did not dramatically shift the IC50 concentration of cyclopamine needed to inhibit Gli activity in these cells.
Furthermore, binding studies showed that oxysterols did not compete with fluorescently labeled cyclopamine, BODIPYcyclopamine, for direct binding to Smoothened. These findings demonstrate that oxysterols stimulate hedgehog pathway activity by indirectly activating the seven-transmembrane pathway component Smoothened. Osteoinductive oxysterols are therefore novel activators of the hedgehog pathway in pluripotent mesenchymal cells, and they may be important modulators of this critical signaling pathway that regulates numerous developmental and post-developmental processes.
The Hedgehog (Hh) 1 signaling pathway is indispensable for normal patterning of multicellular embryos and also functions in postembryonic development and in adult tissue homeostasis, including regulation of stem cell physiology (1) (2) (3) . Reduced Hh pathway activity can cause severe developmental defects in mice and humans, and aberrant increases in Hh pathway activity are associated with cancer (4) (5) . Given these roles in various pathological conditions, small molecules that modulate Hh pathway activity represent potential therapeutic agents as well as pharmacological tools for probing the mechanisms of signal transduction.
Hh signaling begins with the release from producing cells of a doubly lipid-modified Hh protein that binds to the 12-transmembrane spanning receptor Patched (Ptch) on Hh responsive cells, relieving suppression of the 7-transmembrane protein, Smoothened (Smo). Smo in turn activates an intracellular signaling cascade that results in activation of the Gli transcription factor(s), which in turn mediate the transcription of the Hh target genes, including Gli-1 and Ptch. Mice lacking Sonic hedgehog (Shh) function fail to develop most craniofacial bones and exhibit marked defects in the skeletal derivatives of the sclerotome, including absence of a vertebral column and calcified ribs (6) . Mice lacking function of the Indian hedgehog (Ihh) gene display defects in endochondral bone patterning and a deficit in osteoblast formation, resulting in stunted and disorganized limbs (7) . These defects indicate a requirement for Hh signaling in the specification and differentiation of the axial and appendicular skeleton. Several studies have demonstrated the lineage-specific differentiation of pluripotent mesenchymal stem cells into osteoblasts upon Hh protein stimulation (8) (9) (10) .
Furthermore, the expression of molecules that stimulate osteoblast differentiation, including bone morphogenetic proteins-2, -4, and -7 (11, 12) and Wnt7b (13) , is regulated by Hh signaling. Due to the decline in osteoprogenitor and osteoblast numbers and function observed in conditions such as senile and postmenopausal osteoporosis (14) , identification of molecules with the potential to stimulate the differentiation of osteoprogenitors into mature, bone-forming osteoblasts is of great therapeutic interest. (15, 16) .
Oxysterols are products of cholesterol oxidation found in the circulation and in tissues. Oxysterols can be derived from the diet or from endogenous cellular biosynthesis, and they play important roles in physiological and pathological processes. We previously reported that specific oxysterols, namely 20(S)-hydroxycholesterol (20S) in combination with 22(S)-hydroxycholesterol (22S) or 22(R)-hydroxycholesterol (22R) have potent osteoinductive properties when applied to marrow stromal cells (17, 18) . This effect was evidenced from increased DNA binding activity of Runx2, the transcriptional regulator of osteoblastic gene expression, increased alkaline phosphatase (ALP) activity, important in mineralization of extracellular matrix and increased expression of osteocalcin (OCN), an osteoblast specific gene. Significant increases in mineralized matrix, the ultimate measure of osteoblast function, were also observed with oxysterol treatment (17) . Here we report that the osteoinductive effects of oxysterols are mediated by activation of the Hh signaling pathway. Furthermore, competition and binding studies strongly suggest that the effect of oxysterols on Hh pathway activity occurs upstream of Smo.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents -M2-10B4 cells, C3H10T1/2 cells, Smo-/-mouse embryonic fibroblasts (MEFs) and Ptch-/-MEFs were maintained as previously described (16, 17, 19, 20) . Treatments were performed in differentiation medium containing 5% fetal bovine serum, 50 µg/ml ascorbate and 3 mM β-glycerophosphate. BODIPY-cyclopamine was from TRC (North York, Ontario, Canada), tetracycline was purchased from Sigma, and sodium butyrate was from J. T. Baker (Mallinchrodt Baker, Phillipsburg, NJ). Blasticidin and Geneticin were from Invitrogen (Carlsbad, CA).
Microarray -All samples were processed, scanned and quality checked on Affymetrix HG-U133A arrays (21) . For analysis of gene expression measures, all Affymetrix data was normalized using model-based expression and the pair matched -mismatched method from dChip (22) . Subsequent to this, probesets that showed at least a 2 fold change in expression, a minimum difference in expression of 100, and a 2 sided t-test p-value of < .01 between the two groups were selected out for further analysis. Comparisons were made for all experimental vs. all control, and also for experimental vs. control comparisons at 8 and 48 hour time points specifically. The lists generated in this way were then put through an EASE analysis (23) (26) . Oligonucleotides were annealed to their complementary sequences by boiling and cooling. The probes were end-labeled with γ 32 P-ATP using polynucleotide kinase and column purified. Nuclear extracts were prepared using the modified Dignam protocol (27) . Nuclear extracts (10µg) were incubated in binding buffer (10mM Tris pH 7.5, 100mM NaCl, 1mM DTT, 1mM EDTA, 4% glycerol), 1µg poly(dIdC) and 0.2ng of labeled probe for 20 minutes at room temperature, and complexes were resolved on a cooled, 6% acrylamide 1X TBE gel. Subsequently, gels were dried and exposed to film.
Alkaline Phosphatase Activity Assay, Northern
Blotting and Mineralization Assay-Colorimetric alkaline phosphatase activity assay on whole cell extracts was performed as previously described (17) . Northern blotting for OCN and 18S rRNA was performed as previously described (17) . Gene expression was quantified using a Storm840 phosphorimager and ImageQuant software (Amersham, Piscataway, NJ).
Construction of the Tetracycline-Regulated Smo
Expression Plasmid, pACMV-tetO-Smo-Myc -The Smo-Myc gene was amplified from the plasmid pGE-Smo-Myc (20) using the primers 5'-AAAAT GAATT CAACA ACTCC GCCCC ATTGA C-3' and 5'-CCCGC GCGGC CGCCG ACTAC GACCT AATTC CTGC-3'. The resulting PCR product was digested with HindIII to isolate the Smo-Myc gene, end-repaired by using the DNA polymerase I Klenow fragment, and then digested with NotI. The Smo-Myc gene was purified by agarose gel electrophoresis and inserted into the plasmid pACMV-tetO, as previously described (28) , to give the vector pACMV-tetO-Smo-Myc.
Construction of Stable HEK293S Cell Lines for
Tetracycline-Induced Smo Gene Expression -HEK293S-TetR cells were maintained and stably transfected with pACMV-tetO-Smo-Myc as described (28) .
Individual Geneticin-resistant colonies were expanded and screened for SmoMyc expression by analyzing solubilized cell extracts by SDS-PAGE followed by immunodetection with anti-Myc polyclonal antibody. One cell line exhibiting tetracyclineinducible Smoothened expression was chosen and expanded for use in all subsequent experiments.
BODIPY-cyclopamine Binding Assay -HEK293S stable cell lines containing the inducible Smoothened gene were grown to confluence in medium containing Geneticin (2 mg/ml) by using 6-well plates. The growth medium was then replaced with fresh medium containing tetracycline (1 µg/ml) and sodium butyrate (5 mM). After 2 d, fluorescence binding assays using BODIPY-cyclopamine were conducted as previously described (29) .
Western blotting -After treatments, cells were lysed in lysis buffer, protein concentrations determined using the Bio-Rad protein assay (Hercules, CA), and SDS-PAGE was performed as previously described (17), probing for native and phosphorylated proteins.
Statistical Analyses -Computer-assisted statistical analyses were performed using the StatView 4.5 program. All p-values were calculated using ANOVA and Fisher's projected least significant difference (PLSD) significance test. A value of p<0.05 was considered significant. To further examine Hh pathway activation by oxysterols, a reporter assay using a luciferase reporter driven by a multimerized Gli-responsive element (5'-GAACACCCA-3') (Gli-luc) was used (15) . M2 cells transfected with Gli-luc and treated with SS showed a 5-fold increase in luciferase activity over control vehicle-treated cells ( Figure  1c) . Similar results were noted upon treatment of cells with ShhN (200 ng/ml), and induction by oxysterols or ShhN was inhibited by pre-treatment with the Hh pathway inhibitor, cyclopamine (29) . Induction of Gli reporter activity was not observed for non-osteoinductive oxysterols, including 7-α-hydroxycholesterol and 7-ketocholesterol ( Figure  1d ) (17), thus further supporting a role for Hh pathway activity in oxysterol-induced osteogenesis.
RESULTS

Hedgehog Pathway Activation by Osteogenic
Role of Liver X Receptor in Hh Pathway
Activation -As specific oxysterols, including 20S and 22R, are known agonists of the nuclear hormone receptor liver X receptor (LXR) (30) , and since LXR is expressed in M2 cells (17), we examined whether activation of LXR could lead to increased Hh signaling. Gli-luc reporter assay showed no activation in cells treated with 1 or 5 µM of the synthetic LXR agonist, TO-901317 (TO) (Figure 1d ). This is consistent with our previous finding that activation of LXR in M2 cells by similar concentrations of TO does not induce, but actually inhibits osteoblastic differentiation (17) . Such potentially adverse activation of LXR by osteoinductive oxysterols, such as 20S, emphasizes the importance of developing strategies that would limit its concentration if used therapeutically for osteopenic disorders.
Combination oxysterol treatment using 20S with 22S, which is not an LXR agonist and appears to enhance the osteoinductive effects of 20S (17), is one such strategy.
Hh Pathway Activation Mediates OxysterolInduced Osteoblastic Differentiation -To determine the functional role of Hh signaling in oxysterol-induced osteoblastic differentiation, the effect of cyclopamine on oxysterol-induced markers of osteoblastic differentiation in M2 cells was evaluated. We found that the substantial induction in ALP activity produced by SS treatment was significantly inhibited by cyclopamine in a dose-dependent manner ( Figure  2a) . Similarly, EMSA analysis demonstrated that cyclopamine completely inhibited the stimulation of Runx2 DNA binding activity in oxysteroltreated cells (Figure 2b) . Furthermore, oxysterolinduced expression of OCN, a Runx2 target gene, and increased mineralization in cultures of M2 cells, were inhibited by cyclopamine (Figure 2c,d) .
Altogether, these findings demonstrate that the Hh signaling pathway is essential for the osteoinductive effects of oxysterols.
Mechanism of Oxysterol-Induced Hh Pathway
Activation -To elucidate the mechanism by which oxysterols cause Hh pathway activation, we first examined whether oxysterols induce the expression of endogenous Hh molecules by M2 cells. Q-RT-PCR analysis showed that oxysterol treatment (5 µM SS) of M2 cells for up to 48 hours produced no change in the low levels of Ihh mRNA present in vehicle-treated control cells, and that Shh mRNA in M2 cells was undetectable with or without oxysterol treatment (data not shown). Furthermore, a Shh neutralizing antibody did not inhibit oxysterol-induced ALP activity in M2 cells, whereas it completely inhibited ALP activity induced by exogenously added ShhN (Figure 3 ). These results suggest that oxysterols do not affect endogenous Hh expression levels and must therefore cause Hh pathway activation via a different mechanism, perhaps by modulating other members of the Hh signaling network such as Smo and/or Ptch.
To examine this possibility, mouse embryonic fibroblasts from Smo -/-and Ptch -/-null mice were used. To demonstrate that MEFs from mutant mouse embryos are an appropriate model system to further characterize the mechanism of oxysterol-induced Hh pathway activity, we first tested the effects of osteogenic sterols on wild-type C3H10T1/2 MEFs. Similar to the pluripotent marrow stromal cells, we found that C3H10T1/2 cells undergo osteoblastic differentiation in response to oxysterols, as assessed by the induction of ALP activity ( Figure  4a ) and Runx2 DNA binding activity (manuscript in Press). Treatment with oxysterols also induced Gli-luc activity in C3H10T1/2 cells and this activity was inhibited by cyclopamine pretreatment (Figure 4b) . In contrast to wild type MEFs, Smo-/-MEFs had very low Gli-luc activity and were unresponsive to treatment with oxysterols or with conditioned medium containing ShhN (ShhN-CM) (Figure 4c ). Responsiveness to SS and ShhN-CM was restored by transfection of a Smo expression vector, with no change in baseline reporter activity (Figure 4c) . Smo -/-MEFs also failed to undergo osteoblastic differentiation in response to oxysterols (Figure  4d ), although treatment with bone morphogenetic protein 7 (BMP-7), did induce ALP activity in Smo-/-MEFs, thus bypassing the requirement for Hh pathway activity and confirming the inherent ability of these cells to differentiate along the osteoblastic lineage (Figure 4d 
We next examined the possibility that oxysterols may stimulate Hh pathway activity by directly binding to and activating Smo, as previously demonstrated for pathway agonists Smo agonist (SAG) (15) and purmorphamine (16) . Gli-luc reporter activity in Ptch-/-MEFs can be suppressed in a dose-dependent manner by treatment with the Smo antagonist cyclopamine, which acts by directly binding to and inhibiting Smo (29) (Figure 4f ). If oxysterols act by binding to and activating Smo, then a shift in the effective concentration of cyclopamine required for pathway inhibition would be expected. For example, the IC50 of cyclopamine action is shifted by several orders of magnitude upon treatment with Hh pathway-activating concentrations of the Smo agonists SAG and purmorphamine (15, 16) . We noted, however, that oxysterols did not cause dramatic shifts in the concentrations of cyclopamine required to inhibit Gli-luc activity in Ptch-/-MEFs (Figure 4f ), suggesting that oxysterol action is not directly antagonistic to that of cyclopamine. Furthermore, we tested whether oxysterols can compete for binding of a fluorescent derivative of cyclopamine, BODIPYcyclopamine (B-cyc), to cells expressing Smo. Following induction of Smo expression in HEK293S cells stably transfected with an inducible Smo expression construct, cells were cotreated with oxysterols or the potent cyclopamine derivative KAAD-cyclopamine in the presence of B-cyc and subjected to fluorescence activated cell sorting (FACS) analysis. We found that binding of B-cyc to HEK293S cells overexpressing Smo was not affected by SS, whereas KAADcyclopamine dramatically reduced B-Cyc binding (Figure 4g ).
The Role of Protein Kinase C and Protein
Kinase A in Oxysterol-Induced Hh Pathway Activation -We previously reported that oxysterol-induced osteoblastic differentiation of cells is mediated via protein kinase C (PKC)-and protein kinase A (PKA)-dependent mechanisms (18) . The role of these signaling pathways in regulating the different markers of osteoblastic differentiation appears to be both specific and overlapping (18) .
To begin elucidating the possible role of PKC and PKA in mediating oxysterol-induced Hh pathway activation, we examined the effect of PKC and PKA inhibitors on markers of Hh pathway activation. Pretreament of M2 cells with the PKCδ selective inhibitor, rottlerin, previously found to inhibit osteoblastic differentiation induced by oxysterols, dosedependently inhibited oxysterol-induced Gli-1 and Ptch mRNA expression (Figure 5a,b) . Similarly, oxysterol-induced Gli-1 and Ptch expression was inhibited in cells whose PKC stores were depleted following overnight pretreatment with 1 µM PMA (Figure 5c,d) .
We next examined whether oxysterols induced PKC activation by assessing the levels of phosphorylated MARCKS (pMARCKS), a PKC substrate, by Western blotting. Whole cell lysates from M2 cells treated for 10 min, 30 min, 2 hours, 8 hours, 24 hours or 48 hours with 5 µM SS did not show any increase in pMARCKS levels compared to control untreated cells (data not shown), whereas a 30 min treatment with PMA clearly induced MARCKS phosphorylation.
To examine the possible role of PKA in oxysterol-induced Hh pathway activation, the effect of PKA inhibitor, H-89, previously found to inhibit the induction of some, but not all, markers of osteoblastic differentiation, on oxysterolinduced Gli-1 and Ptch mRNA expression was assessed by Q-RT-PCR. Results showed that pretreatment of M2 cells with H-89 (5-15 µM) did not inhibit oxysterol-induced Gli-1 or Ptch expression after 24 hours of treatment (data not shown). Furthermore, treatment of M2 cells for 24 hours with SS (5 µM) together with the PKA pathway activator, forskolin (10 µM), completely inhibited oxysterol-induced Gli-1 and Ptch expression (data not shown). Finally, Western blotting of whole cell lysates from oxysteroltreated cells showed no significant induction of phosphorylated PKA (pPKA) or phosphorylated CREB (pCREB) levels compared to control untreated cells at similar time points described above for the examination of pMARCKS levels (data not shown). In contrast, a 30 minute treatment with forskolin (10 µM) significantly induced pCREB levels.
DISCUSSION
The present study clearly demonstrates that specific oxysterols induce their osteoinductive effects through activation of the Hh signaling pathway in pluripotent mesenchymal cells. Our data also strongly suggest that, despite a requirement for Smo in oxysterol-mediated Hh pathway activation, oxysterols do not bind to or activate Smo directly. We cannot rule out the possibility that oxysterols may bind Smo at a site distinct from that bound by cyclopamine. However, the inability of oxysterols to antagonize cyclopamine binding or inhibition of Smo suggests that oxysterols are unlikely to directly influence the conformational shift thought to be critical for Smo activation (19) .
Our evidence instead supports a more indirect effect of oxysterols on Smo activity. One possibility for such an effect is that oxysterols might alter Smo subcellular localization in a manner that facilitates activation (31), but without preventing cyclopamine binding and antagonism. Alternatively, oxysterols might exert their effects at a distinct level of the pathway, for example, by inhibiting Ptch activity. Such a possibility is particularly attractive given the presence within Ptch of a region homologous to the sterol sensing domains (SSD) first identified in proteins such as 3-hydroxy-3-methylglutarylCoenzyme A (HMG-CoA) reductase and sterolregulatory element binding protein (SREBP)-cleavage activating protein (SCAP). The SSD within these proteins is involved in sensing and responding to cellular sterol levels; in the case of SCAP, direct binding of cholesterol has been demonstrated (32) . Thus, it is conceivable that direct binding to an oxysterol could modulate Ptch activity. Alternatively, oxysterols could exert their effects through interactions with other proteins or by modulating physical properties of membranes. Moreover, since Ptch is related to the resistancenodulation-cell division family of bacterial pumps and to the Niemann-Pick C1 protein, involved in intracellular cholesterol transport, it has been suggested that it might modulate Smo activity through regulating the distribution of a secondary hydrophobic Smo-interacting endogenous small molecule (20) . Such activity of Ptch might be subject to regulation by oxysterols, allowing for the transport and/or interaction of an activating small molecule with Smo in the presence of oxysterols. However indirect, these effects ultimately would have to impact the activity of a Hh pathway component at or upstream of the level of Smo.
Our data also provide evidence for the involvement of PKC signaling in oxysterolinduced hedgehog pathway activation. Cross-talk between the Hh pathway and several kinases has been reported, including PKCδ (33), MAPK (33), PI3-kinase (34), and PKA (35, 36). Results from the present study using PKC inhibitor, rottlerin, and PKC depletion through PMA pretreatment, are consistent with the role of PKC in mediating oxysterol-induced Hh pathway activation and expression of Hh target genes, Gli1 and Ptch. Interestingly, similar to what has been reported for Shh (33), PKC does not appear to be a downstream target of oxysterols, but rather basal PKC activity appears to be essential for oxysterolinduced expression of Hh target genes. Furthermore, our data are consistent with the negative role of PKA pathway activation in Hh signaling as indicated by the ability of forskolin to completely inhibit oxysterol effects on Gli1 and Ptch expression. However, it must be noted that despite having an inhibitory role on Hh pathway activation, PKA does play a stimulatory role in mediating some of the osteogenic effects of oxysterols (18) . The pro-osteogenic role of PKA is likely to be independent of Hh pathway activation and is likely to target downstream effectors that mediate terminal differentiation of cells into osteoblasts. Similar to PKC, PKA signaling does not appear to be a direct downstream target of oxysterols, and it appears that basal PKA activity is involved in mediating oxysterol effects on osteoblastic differentiation. Although it must be noted that since our studies were carried out using whole cell lysates, we can not rule out any potential activation of PKA or PKC by oxysterols in specific cellular compartments.
Corcoran & Scott recently reported a modest (2-3 fold) activation of Hh pathway activity by certain oxysterols in the cell line PZp53 MED , thought to lack Ptch activity and derived from a medulloblastoma that arose in a Ptch+/-mouse (37). In our studies we observed oxysterol induction of pathway activity by as much as 20-30 fold in wild type cells, and no induction beyond the high constitutive levels present in Ptch-/-fibroblasts. The differences in our observations may result from inherent differences in baseline regulation of Hh pathway signaling in the two cell types, and do not affect our observations that oxysterols fail to antagonize cyclopamine binding to or inhibition of Smo (Figure 4f,g) , and the resulting conclusion that the major effect of osteogenic oxysterols on Hh pathway activation is likely not through direct action on Smo.
Our study provides evidence that specific oxysterols activate the Hh signaling in pluripotent mesenchymal cells as demonstrated by increases in Gli-1 and Ptch mRNA expression and Gli-luc reporter activity.
Given that the identified oxysterols capable of activating Hh signaling are naturally-occurring molecules (38, 39) and that pathway activity is affected in multiple cell types, the present findings have numerous implications in physiological and pathological processes. For example, the role of Hh signaling in skeletal development and maintenance may be regulated at least in part through the action of oxysterols derived from endogenous cellular synthesis or dietary means. We previously reported that nontoxic doses of a cholesterol biosynthetic pathway inhibitor, mevastatin, blocked osteoblastic differentiation of progenitor cells (40), and that sterol depletion by genetic or pharmacological means blocks the cellular response to Hh protein stimulation (41). These findings suggest the possibility that a product(s) of the cholesterol biosynthetic pathway may be capable of modulating Hh pathway activity during embryonic and postembryonic bone formation, as well as in other settings. The present findings further support that possibility by demonstrating that endogenous oxysterols can induce Hh pathway activity and therefore may play roles in osteogenesis and in other developmental processes that are regulated by Hh signaling. The role of Hh pathway activity in pathological processes such as carcinogenesis and metastasis further suggests the possibility that specific oxysterols may play an important role in tumorigenesis. Oxysterols and factors involved in their synthesis and metabolism thus may be relevant not only to the regulation of cholesterol biosynthesis (42), but also to other physiological and pathological processes. 
